Nam W. Kim Ph.D
Chief Executive Officer & Chief Technology Officer
Nam is a seasoned scientist and executive with over 25 years of experience in developing and commercializing novel diagnostics tests at several cutting-edge biotechnology companies including Geron, and diaDexus where he was responsible for the development of novel diagnostic and prognostic markers for cancer and cardiovascular diseases.
President & Chief Operating Officer
Sholeh is a clinical diagnostic expert with over 35 years of clinical diagnostics and life-science industry including Kaiser Permanente, LifeScan (a Johnson & Johnson Company), DiaSorin, Incell Dx and Enzo LifeSciences. She has launched several novel tests both in the U.S. and internationally and managed the sales and marketing activities for ENZO LifeScience in Europe.
Shahram Gholami M.D.
Chief Medical Officer
Shahram is an internationally recognized urologist in the field of minimally invasive laparoscopic and robotic surgery and cystoscopy. He is a practicing clinician with a renowned urology clinic located in the heart of silicon valley and affiliated with Good Samaritan Hospital and Stanford University.
At KDx Diagnostics, we believe in the advancement of bladder cancer recognition. Ever since our establishment in 2016, we have worked endlessly to achieve the highest sensitivity and specificity bladder cancer test. With the creation of our URO17™ test, we have not only achieved such an inexpensive and non-invasive test, but also one that is simpler to use for the patient with results that are more accurate than ever before. We hope with the introduction of the URO17™, we can strive for quicker recognition and response to the dangers of cancer and help out patients achieve a peaceful and care-free life.